No edit summary |
(adding content) |
||
| Line 152: | Line 152: | ||
<!--T:38--> | <!--T:38--> | ||
<br> | |||
===2001: [https://tobaccocontrol.bmj.com/content/10/2/189 Clearing the smoke: the science base for tobacco harm reduction—executive summary]=== | |||
*For the purposes of this report, a product is harm reducing if it lowers total tobacco related mortality and morbidity even though use of that product may involve continued exposure to tobacco related toxicants. | |||
===2001: [https://tobaccocontrol.bmj.com/content/10/3/201 Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction]=== | |||
*As has been pointed out by others,the current regulatory system is upside down, with the more dangerous products (that is, tobacco products) receiving the least regulation and the least dangerous products (that is, MN) subject to the most stringent constraints. | |||
<br> | <br> | ||
edits